Concurrent pegcetacoplan with anti-VEGF linked to slower geographic atrophy progression in nAMD
Key Takeaways
- Concurrent pegcetacoplan and anti-VEGF therapy reduced the rate of geographic atrophy lesion growth by 44%.
- Visual acuity remained stable during 2 years of concurrent treatment.
Concurrent treatment with pegcetacoplan and anti-VEGF injections was associated with a slower rate of geographic atrophy (GA) progression while maintaining stable visual acuity in patients with neovascular age-related macular degeneration (nAMD), according to a study.
The analysis included 31 patients with co-existing nAMD and GA who had received anti-VEGF therapy for at least 1 year before starting pegcetacoplan and continued both treatments concurrently for the following year. Patients with subfoveal GA were excluded. Investigators assessed GA area using multimodal retinal imaging at 5 time points spanning 1 year before and 1 year after pegcetacoplan initiation.
After pegcetacoplan was initiated, the rate of GA lesion growth decreased by 44%, with GA area increasing by 0.22 mm over the following year compared with 0.39 mm during the previous year (P < 0.0001). Patients had been treated for nAMD with anti-VEGF therapy for an average of 6.5 years before receiving concurrent pegcetacoplan.
Patients maintained stable visual acuity, with mean ETDRS letter scores remaining at approximately 68 throughout the 2-year study period (67.5 vs 67.9; P = 0.93).
Reference
Adrean SD, Han W, Hui J, et al. One-Year Results of Geographic Atrophy Patients with Pre-Existing nAMD treated with both anti-VEGF therapy and pegcetacoplan. Retina. 2026;doi: 10.1097/IAE.0000000000004915. Epub ahead of print. PMID: 42467820.
Related Content
